Aliases & Classifications for Aging

MalaCards integrated aliases for Aging:

Name: Aging 57 73

External Ids:

OMIM® 57 502000

Summaries for Aging

OMIM® : 57 Progressive damage to mitochondrial DNA (mtDNA) during life is thought to contribute to aging processes. This notion is supported by the observation of an aging-related accumulation in human mtDNA of oxidative and alkylation derivatives of nucleotides, of small deletions and insertions, and of large deletions, although their low frequency raises questions about their functional significance (Michikawa et al., 1999). (502000) (Updated 05-Apr-2021)

MalaCards based summary : Aging is related to premature aging and werner syndrome. An important gene associated with Aging is BCYRN1 (Brain Cytoplasmic RNA 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and AMP-activated Protein Kinase (AMPK) Signaling. The drugs Methyltestosterone and Testosterone undecanoate have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Senescence (/sɪˈnɛsəns/) or biological aging is the gradual deterioration of functional characteristics.... more...

Related Diseases for Aging

Diseases related to Aging via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1672)
# Related Disease Score Top Affiliating Genes
1 premature aging 32.5 TP63 SOD2 PDGFRB LMNA
2 werner syndrome 32.3 WRN PARP1 LMNA
3 hutchinson-gilford progeria syndrome 32.0 WRN SOD2 SIRT6 SIRT1 LMNA
4 age-related hearing loss 31.1 SOD2 SIRT1 HIF1A
5 huntington disease 30.7 SOD2 SIRT1 REST PPARG FOXO3
6 hyperglycemia 30.7 SOD2 PPARG NAMPT HIF1A
7 non-alcoholic fatty liver disease 30.7 SOD2 SIRT3 SIRT1 PPARG NAMPT
8 osteoporosis 30.6 WRN SOD2 SIRT6 SIRT1 PPARG LMNA
9 type 2 diabetes mellitus 30.4 WRN SOD2 SIRT6 SIRT1 PPARG PARP1
10 disease of mental health 30.3 SOD2 SIRT6 SIRT3 SIRT1 REST PPARG
11 optic atrophy 1 30.3 SOD2 SIRT3 SIRT1
12 body mass index quantitative trait locus 11 30.2 SOD2 SIRT6 SIRT3 SIRT1 PPARG NAMPT
13 non-alcoholic steatohepatitis 30.1 SOD2 SIRT1 PPARG
14 diabetes mellitus 30.1 WRN SOD2 SIRT3 SIRT1 PPARG PARP1
15 peripheral nervous system disease 30.0 SIRT1 PPARG LMNA HIF1A
16 pellagra 29.7 PPARG PARP1 NAMPT
17 tuberous sclerosis 1 29.6 HIF1A FOXO3 FOXO1
18 medulloblastoma 28.8 WRN SIRT1 REST PDGFRB PARP1 HIF1A
19 premature aging syndrome, penttinen type 11.5
20 mild cognitive impairment 11.3
21 dementia 11.3
22 alzheimer disease 11.2
23 fontaine progeroid syndrome 11.2
24 branchiooculofacial syndrome 11.2
25 short stature, hearing loss, retinitis pigmentosa, and distinctive facies 11.2
26 premature aging syndrome, okamoto type 11.2
27 cockayne syndrome 11.1
28 impotence 11.0
29 gapo syndrome 11.0
30 presbyopia 11.0
31 refractive error 11.0
32 wiedemann-rautenstrauch syndrome 10.9
33 acrogeria, gottron type 10.9
34 nestor-guillermo progeria syndrome 10.9
35 sleep disorder 10.9
36 cerebroretinal microangiopathy with calcifications and cysts 2 10.9
37 ogden syndrome 10.9
38 laminopathy with premature aging 10.9
39 cerebral amyloid angiopathy, cst3-related 10.9
40 rickets 10.9
41 progeroid syndrome 10.9
42 ataxia-telangiectasia 10.9
43 intraocular pressure quantitative trait locus 10.9
44 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.9
45 senile cataract 10.9
46 arthritis 10.9
47 trichothiodystrophy 10.9
48 rothmund-thomson syndrome, type 2 10.8
49 longevity 1 10.8
50 williams-beuren syndrome 10.8

Graphical network of the top 20 diseases related to Aging:



Diseases related to Aging

Symptoms & Phenotypes for Aging

Clinical features from OMIM®:

502000 (Updated 05-Apr-2021)

GenomeRNAi Phenotypes related to Aging according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 9.77 NAMPT
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.77 NAMPT
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.77 NAMPT
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.77 NAMPT SIRT3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.77 NAMPT
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.77 NAMPT SIRT3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.77 FOXO3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 9.77 NAMPT
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.77 NAMPT
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 9.77 HIF1A
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 9.77 NAMPT
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.77 NAMPT
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.77 NAMPT
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 9.77 PPARG
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.77 HIF1A
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 9.77 NAMPT
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.77 NAMPT
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-208 9.77 FOXO3
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-32 9.77 FOXO3
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 9.77 NAMPT
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 9.77 NAMPT
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.77 NAMPT
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-69 9.77 NAMPT
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 9.77 HIF1A
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-82 9.77 SIRT3
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.77 SIRT3

MGI Mouse Phenotypes related to Aging:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.53 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
2 cardiovascular system MP:0005385 10.51 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
3 behavior/neurological MP:0005386 10.49 DAO FOXO1 FOXO3 HIF1A LMNA PARP1
4 growth/size/body region MP:0005378 10.47 FOXO1 GDF11 HIF1A LMNA NAMPT PARP1
5 homeostasis/metabolism MP:0005376 10.47 DAO FOXO1 FOXO3 GDF11 HIF1A LMNA
6 immune system MP:0005387 10.4 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
7 integument MP:0010771 10.39 FOXO1 FOXO3 HIF1A LMNA NAMPT PARP1
8 mortality/aging MP:0010768 10.39 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
9 adipose tissue MP:0005375 10.36 FOXO1 FOXO3 LMNA PDGFRB PPARG RGN
10 hematopoietic system MP:0005397 10.36 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
11 endocrine/exocrine gland MP:0005379 10.32 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
12 digestive/alimentary MP:0005381 10.29 FOXO1 FOXO3 GDF11 HIF1A LMNA PDGFRB
13 embryo MP:0005380 10.28 FOXO1 GDF11 HIF1A NAMPT PARP1 PDGFRB
14 craniofacial MP:0005382 10.25 FOXO1 GDF11 HIF1A LMNA PDGFRB SIRT1
15 nervous system MP:0003631 10.21 DAO FOXO1 FOXO3 GDF11 HIF1A LMNA
16 limbs/digits/tail MP:0005371 10.15 FOXO1 GDF11 HIF1A LMNA PDGFRB RGN
17 liver/biliary system MP:0005370 10.13 FOXO1 HIF1A LMNA PPARG RGN SIRT1
18 hearing/vestibular/ear MP:0005377 10.1 FOXO3 LMNA PARP1 PPARG REST RGN
19 muscle MP:0005369 10.03 FOXO1 GDF11 HIF1A LMNA PDGFRB PPARG
20 neoplasm MP:0002006 10.01 FOXO1 FOXO3 HIF1A PPARG SIRT1 SOD2
21 renal/urinary system MP:0005367 9.96 FOXO3 GDF11 HIF1A LMNA PARP1 PDGFRB
22 reproductive system MP:0005389 9.93 FOXO1 FOXO3 LMNA PARP1 PDGFRB PPARG
23 normal MP:0002873 9.92 FOXO1 HIF1A LMNA PDGFRB PPARG SIRT1
24 skeleton MP:0005390 9.77 FOXO1 FOXO3 GDF11 HIF1A LMNA PDGFRB
25 vision/eye MP:0005391 9.5 FOXO3 GDF11 HIF1A LMNA NAMPT PARP1

Drugs & Therapeutics for Aging

Drugs for Aging (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1462)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4 58-18-4 6010
2
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
3
Testosterone enanthate Approved Phase 4 315-37-7 9416
4
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
5
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
6
Lactulose Approved Phase 4 4618-18-2 11333
7
Desogestrel Approved Phase 4 54024-22-5 40973
8
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
9
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
10
Coal tar Approved Phase 4 8007-45-2
11
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
12
Abciximab Approved Phase 4 143653-53-6
13
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
14
Lorazepam Approved Phase 4 846-49-1 3958
15
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
16
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
17
Sulfamethoxazole Approved Phase 4 723-46-6 5329
18
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
19
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
20
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
21
Metronidazole Approved Phase 4 443-48-1 4173
22
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
23
Ondansetron Approved Phase 4 99614-02-5 4595
24
Clarithromycin Approved Phase 4 81103-11-9 84029
25
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
26
Ethambutol Approved Phase 4 74-55-5 3279 14052
27
Fospropofol Approved, Illicit, Investigational Phase 4 258516-89-1, 258516-87-9 3038498
28
Morphine Approved, Investigational Phase 4 57-27-2 5288826
29
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
30
Nevirapine Approved Phase 4 129618-40-2 4463
31
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
32
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
33
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
34
Budesonide Approved Phase 4 51333-22-3 63006 5281004
35
Ferrous fumarate Approved Phase 4 141-01-5
36
Phenol Approved, Experimental Phase 4 108-95-2 996
37
Tirofiban Approved Phase 4 144494-65-5 60947
38
Cangrelor Approved Phase 4 163706-06-7 9854012
39
Insulin aspart Approved Phase 4 116094-23-6 16132418
40
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
41
carbamide peroxide Approved Phase 4 124-43-6
42
Retapamulin Approved Phase 4 224452-66-8 6918462
43
Benzoyl peroxide Approved Phase 4 94-36-0 7187
44
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
45
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
46
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
47
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
48
Miltefosine Approved, Investigational Phase 4 58066-85-6 3600
49
Haloperidol Approved Phase 4 52-86-8 3559
50
Vinorelbine Approved, Investigational Phase 4 71486-22-1 60780 44424639

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Medication Induced Blood Pressure Reduction; Assessment of Cerebral Perfusion and Cognition in Hypertensive Elderly Unknown status NCT00966199 Phase 4 anti-hypertensive medication
2 Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
3 Comparing Effectiveness of Post-operative Analgesia Between Patient Re-education and the Additional of a Basal Morphine Infusion to IV-PCA Morphine in Patients With Unsatisfactory Analgesia After Laparotomy Unknown status NCT02523846 Phase 4 morphine
4 Phase 4 Study of Balanced Propofol Sedation Versus Propofol Alone Sedation Unknown status NCT01321047 Phase 4 Propofol;BPS
5 The Effect of a Circuit Resistance Training, Empagliflozin or "Vegeterranean Diet" on Physical and Metabolic Function in Elderly Subjects With Type 2 Diabetes: a Study Protocol for a Randomized Control Trial (CEV-65 Trial) Unknown status NCT03560375 Phase 4 Empagliflozin 10 MG
6 Multicenter Study Evaluating the Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years. A Prospective, Randomized Study. Unknown status NCT03177434 Phase 4 polyethylene glycols (PEG) 3350;Lactulose Oral Product
7 Inhaled Salbutamol in Elective Caesarean Section Unknown status NCT01978418 Phase 4 salbutamol;Placebo
8 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
9 Effect of Dobutamine as Compared to Dopamine on Cerebral Oxygenation, Mean Arterial Pressure and Cerebral Hemodynamics in Term and Preterm Neonates With Arterial Hypotension Unknown status NCT01427686 Phase 4 Dobutamine;Dopamine
10 The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound Unknown status NCT00813631 Phase 4
11 Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users Unknown status NCT02945293 Phase 4
12 A Prospective Evaluation of Capecitabine and Metabolite Pharmacokinetics in Elderly Breast and Colorectal Cancer Patients and Their Association With Toxicity and Molecular Markers of Enzyme Activity and Aging Unknown status NCT03465202 Phase 4 Capecitabine
13 An Open-Label Pilot Study to Compare the Efficacy of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Unknown status NCT01583478 Phase 4
14 a Randomized Control Trial to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Small for Gestational Age and Appropriate for Gestational Age Infants at 1 Year Unknown status NCT03171324 Phase 4 Iron Supplement
15 AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study Unknown status NCT03005236 Phase 4 ENVARSUS;Standard twice daily tacrolimus
16 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
17 A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
18 Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pressure Patching: A Prospective, Randomized, Placebo Controlled Trial Unknown status NCT03918590 Phase 4 nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX);Theratears tear drop, (Akron, Ann 111 Arbor, MI)
19 Comparison of Early Intervention of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV Patients With Initial Loading Dose Unknown status NCT02864472 Phase 4 Ranibizumab;ranibizumab PRN
20 Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Unknown status NCT02810808 Phase 4 Ranibizumab
21 On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD. Unknown status NCT01670162 Phase 4 Aflibercept
22 Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results Unknown status NCT01657669 Phase 4 Intravitreal Aflibercept injection
23 Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept Unknown status NCT03468296 Phase 4 Intravitreal Aflibercept Injection 2mg
24 Early Cognitive Function and Recovery in Elderly Patients After Laser Laryngeal Surgery: Desflurane-based vs Propofol-based Anesthesia Unknown status NCT03194074 Phase 4 Propofol;Desflurane
25 Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910) Unknown status NCT01961414 Phase 4 Aflibercept
26 A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD). Unknown status NCT01918878 Phase 4 Aflibercept (EYLEA)
27 Influence on Incidence of Postoperative Delirium by Various Sedatives in Elderly Patients With Hip Fracture Under Lumbar Anesthesia: A Randomized, Control and Multi-center Trial Unknown status NCT03346226 Phase 4 Dexmedetomidine Hydrochloride;Propofol
28 Rationalization of the Systemic Treatment of Age-related Macular Degeneration With Rheohemapheresis (RHF) Unknown status NCT01943396 Phase 4
29 A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines Unknown status NCT01841671 Phase 4
30 Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial. Unknown status NCT02242188 Phase 4 Iron
31 Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Unknown status NCT01158846 Phase 4 prasugrel/bivalirudin;clopidogrel/abciximab
32 Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old Unknown status NCT02806531 Phase 4
33 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Unknown status NCT02959801 Phase 4
34 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
35 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
36 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
37 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
38 Oxidative Stress In Semen And Male Infertility Unknown status NCT03464656 Phase 4 Fairhaven Pro for men
39 A Randomized Clinical Trial Comparing Standard and Invidualized Bowel Preparation for Colonoscopy Unknown status NCT03428724 Phase 4 Standard Preparation;Individualized Preparation
40 The Acute Effects of Moderate Intensity Exercise and Caffeine Ingestion on Cognition in Non-Caffeine Consumers and Caffeine Consumers Unknown status NCT03400423 Phase 4 Caffeine
41 mRNA Expression as a Biomarker of Xolair (Omalizumab) Response Unknown status NCT01584687 Phase 4
42 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
43 Influence of Albumin on the Development of Acute Renal Dysfunction Associated With Cardiac Surgery Under Extracorporeal Circulation Unknown status NCT03373318 Phase 4 Human albumin;Plasmalyte
44 Randomized Control Trial of Dichloroacetate, Preoperative Carbohydrate Loading and Moderate Intensity Exercise on Muscle Insulin Resistance After Major Abdominal Surgery Unknown status NCT02469337 Phase 4 Dichloroacetate
45 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
46 EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial Unknown status NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
47 The Assessment of the Effect of Vitamin D Supplementation on the Serum of AGES and Endothelialy Factors and Gene Expression of Glyoxalase Enzyme and YKL-40 Factor in PBMC Cells in the Patients With Type 2 Diabetes . Unknown status NCT03008057 Phase 4
48 Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau Unknown status NCT02953327 Phase 4
49 Three Batches Consistency, Immunity Duration and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China Unknown status NCT03893747 Phase 4
50 A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With ADHD in Fed Condition Unknown status NCT02470234 Phase 4 Methylphenidate HCl ER Capsules

Search NIH Clinical Center for Aging

Genetic Tests for Aging

Anatomical Context for Aging

MalaCards organs/tissues related to Aging:

40
Skin, Brain, Bone, Eye, Endothelial, Myeloid, Skeletal Muscle

Publications for Aging

Articles related to Aging:

(show top 50) (show all 30018)
# Title Authors PMID Year
1
Short telomeres are sufficient to cause the degenerative defects associated with aging. 57
19944403 2009
2
Increased cell-to-cell variation in gene expression in ageing mouse heart. 57
16791200 2006
3
Lamin A-dependent nuclear defects in human aging. 57
16645051 2006
4
Gene regulation and DNA damage in the ageing human brain. 57
15190254 2004
5
Strikingly higher frequency in centenarians and twins of mtDNA mutation causing remodeling of replication origin in leukocytes. 57
12538859 2003
6
Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. 57
12483296 2003
7
Genome dynamics in aging mice. 57
12421760 2002
8
Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. 57
11274426 2001
9
Distinct spectra of somatic mutations accumulated with age in mouse heart and small intestine. 57
10900004 2000
10
Role of nuclear background and in vivo environment in variable segregation behavior of the aging-dependent T414G mutation at critical control site for human fibroblast mtDNA replication. 57
15328912 1999
11
Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. 57
10531063 1999
12
Mitochondrial genotype associated with longevity. 57
9449878 1998
13
Accumulation of deletions in human mitochondrial DNA during normal aging: analysis by quantitative PCR. 57
1463763 1992
14
Growing old: the most common mitochondrial disease of all? 57
1303273 1992
15
Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. 57
1303287 1992
16
Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. 57
1303288 1992
17
Evidence for and against the causal involvement of mitochondrial DNA mutation in mammalian ageing. 57
1383763 1992
18
Mitochondrial genetics: a paradigm for aging and degenerative diseases? 57
1533953 1992
19
Icariin improves brain function decline in aging rats by enhancing neuronal autophagy through the AMPK/mTOR/ULK1 pathway. 61
33556283 2021
20
Alterations of long non-coding RNA and mRNA profiles associated with extracellular matrix homeostasis and vascular aging in rats. 61
33645431 2021
21
Mechanical Properties of Epoxy Adhesive Under Thermal Aging and Their Chemical Degradation Behavior. 61
33714342 2021
22
Multiple chronic conditions and risk of cognitive impairment and dementia among older Americans: findings from the Aging, Demographics, and Memory Study (ADAMS). 61
32633198 2021
23
Freezing-then-aging treatment improved the protein digestibility of beef in an in vitro infant digestion model. 61
33626399 2021
24
Rapid automatized naming (RAN): effects of aging on a predictor of reading skill. 61
32799742 2021
25
AhR/miR-23a-3p/PKCα axis contributes to memory deficits in ovariectomized and normal aging female mice. 61
33738140 2021
26
Protocol for comprehensive RNA sequencing analysis of murine long non-coding RNAs during aging. 61
33786463 2021
27
Astaxanthin alleviates pathological brain aging through the upregulation of hippocampal synaptic proteins. 61
33269751 2021
28
Adsorption and desorption behaviors of antibiotics by tire wear particles and polyethylene microplastics with or without aging processes. 61
33736173 2021
29
Aging-Dependent Mitophagy Dysfunction in Alzheimer's Disease. 61
33417222 2021
30
Resilience in the suprachiasmatic nucleus: Implications for aging and Alzheimer's disease. 61
33516909 2021
31
Review of the artificially-accelerated aging technology and ecological risk of microplastics. 61
33736298 2021
32
Blood pressure as a predictor of everyday cognitive function in aging adults with and without fibromyalgia. 61
32339069 2021
33
Volatile compounds sorption during the aging of Chinese Liquor (Baijiu) using Pottery Powder. 61
33310558 2021
34
BaZiBuShen alleviates altered testicular morphology and spermatogenesis and modulates Sirt6/P53 and Sirt6/NF-κB pathways in aging mice induced by D-galactose and NaNO2. 61
33508368 2021
35
Deterioration of nuclear morphology and architecture: A hallmark of senescence and aging. 61
33540043 2021
36
Feed-forward regulation between cellular senescence and immunosuppression promotes the aging process and age-related diseases. 61
33581314 2021
37
Microglia and modifiable life factors: Potential contributions to cognitive resilience in aging. 61
33640394 2021
38
Aging adipose: Depot location dictates age-associated expansion and dysfunction. 61
33515751 2021
39
Preventive electroacupuncture reduces cognitive deficits in a rat model of D-galactose-induced aging. 61
33229729 2021
40
Reduced insulin/IGF1 signaling prevents immune aging via ZIP-10/bZIP-mediated feedforward loop. 61
33666644 2021
41
Racial differences of early vascular aging in children and adolescents. 61
32444927 2021
42
Editorial: Interplay between systemic health features and gut dysbiosis in aging and clinical (wasting) conditions. 61
33741754 2021
43
Effects of Fish Oil Combined with Selenium and Zinc on Learning and Memory Impairment in Aging Mice and Amyloid Precursor Protein Processing. 61
32666432 2021
44
Altered expression of the vitamin D metabolizing enzymes CYP27B1 and CYP24A1 under the context of prostate aging and pathologies. 61
33596463 2021
45
Epigenetic enzymes: A role in aging and prospects for pharmacological targeting. 61
33657446 2021
46
Cognitive variability, brain aging, and cognitive decline in late-life major depression. 61
33169874 2021
47
Poria cocos (Fuling) targets TGFβ/Smad7 associated collagen accumulation and enhances Nrf2-antioxidant mechanism to exert anti-skin aging effects in human dermal fibroblasts. 61
33336893 2021
48
Aging-related changes in the sensitivity of behavioral effects of the neonicotinoid pesticide clothianidin in male mice. 61
33609686 2021
49
Pasteurized non-fermented cow's milk but not fermented milk is a promoter of mTORC1-driven aging and increased mortality. 61
33571703 2021
50
The conserved alternative splicing factor caper regulates neuromuscular phenotypes during development and aging. 61
33508255 2021

Variations for Aging

Expression for Aging

Search GEO for disease gene expression data for Aging.

Pathways for Aging

Pathways related to Aging according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1 12.37 SOD2 SIRT3 SIRT1 PPARG NAMPT
2
Show member pathways
12.32 SIRT1 PPARG FOXO3 FOXO1
3
Show member pathways
12.09 SIRT6 SIRT3 SIRT1 HIF1A
4
Show member pathways
12.08 SIRT6 SIRT3 SIRT1 PARP1 NAMPT
5
Show member pathways
12.06 PDGFRB LMNA FOXO3 FOXO1
6
Show member pathways
11.95 SOD2 SIRT1 PPARG FOXO3 FOXO1
7
Show member pathways
11.93 SOD2 SIRT1 FOXO3 FOXO1
8 11.8 HIF1A FOXO3 FOXO1
9 11.78 PPARG NAMPT LMNA HIF1A FOXO1
10 11.71 PPARG FOXO3 FOXO1
11 11.61 SIRT1 FOXO3 FOXO1
12 11.6 SIRT6 SIRT3 PDGFRB HIF1A
13 11.52 SIRT6 SIRT3 SIRT1 PPARG
14
Show member pathways
11.35 SOD2 LMNA FOXO3
15 11.3 SOD2 SIRT1 FOXO3 FOXO1
16 11.05 SIRT3 SIRT1 FOXO3 FOXO1
17 10.86 SIRT6 SIRT1
18 10.64 WRN SIRT6 SIRT3 SIRT1
19 10.27 SIRT3 SIRT1 PPARG PARP1 NAMPT HIF1A

GO Terms for Aging

Cellular components related to Aging according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.13 WRN TP63 SOD2 SIRT6 SIRT1 RGN
2 nucleus GO:0005634 10.03 WRN TP63 SIRT6 SIRT3 SIRT1 RGN
3 protein-containing complex GO:0032991 9.5 TP63 SIRT3 SIRT1 PARP1 HIF1A GDF11
4 nucleoplasm GO:0005654 9.44 WRN TP63 SIRT6 SIRT3 SIRT1 REST

Biological processes related to Aging according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 10.05 TP63 SIRT1 REST PPARG FOXO1
2 positive regulation of transcription, DNA-templated GO:0045893 10.03 TP63 REST PPARG HIF1A FOXO3 FOXO1
3 cellular response to DNA damage stimulus GO:0006974 10.02 WRN TP63 SIRT1 PARP1 FOXO1
4 negative regulation of cell proliferation GO:0008285 10.01 SOD2 REST PPARG LMNA GDF11
5 negative regulation of apoptotic process GO:0043066 9.99 SOD2 SIRT1 RGN PDGFRB HIF1A FOXO1
6 negative regulation of transcription by RNA polymerase II GO:0000122 9.86 TP63 SIRT6 SIRT1 REST PPARG PARP1
7 positive regulation of apoptotic process GO:0043065 9.85 SIRT1 REST PPARG PDGFRB FOXO3 FOXO1
8 cellular response to insulin stimulus GO:0032869 9.82 PPARG PARP1 FOXO1
9 positive regulation of transcription by RNA polymerase II GO:0045944 9.81 TP63 SIRT1 REST PPARG PARP1 NAMPT
10 cellular response to starvation GO:0009267 9.79 WRN SIRT1 FOXO1
11 positive regulation of autophagy GO:0010508 9.75 HIF1A FOXO3 FOXO1
12 cellular response to oxidative stress GO:0034599 9.73 SOD2 PARP1 FOXO3 FOXO1
13 response to hydrogen peroxide GO:0042542 9.72 SOD2 SIRT1 PDGFRB
14 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.7 PPARG HIF1A FOXO3
15 cell aging GO:0007569 9.67 WRN TP63 SIRT1
16 response to lipid GO:0033993 9.66 PPARG PDGFRB
17 multicellular organism aging GO:0010259 9.65 WRN TP63
18 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.64 SOD2 SIRT1
19 white fat cell differentiation GO:0050872 9.64 SIRT1 PPARG
20 DNA synthesis involved in DNA repair GO:0000731 9.63 WRN SIRT1
21 positive regulation of vascular associated smooth muscle cell apoptotic process GO:1905461 9.63 SOD2 PPARG
22 negative regulation of cardiac muscle hypertrophy in response to stress GO:1903243 9.61 LMNA FOXO1
23 retina vasculature development in camera-type eye GO:0061298 9.6 PDGFRB HIF1A
24 peptidyl-lysine deacetylation GO:0034983 9.59 SIRT3 SIRT1
25 oxygen homeostasis GO:0032364 9.58 SOD2 HIF1A
26 negative regulation of cellular senescence GO:2000773 9.58 TP63 SIRT1 NAMPT
27 cellular response to hyperoxia GO:0071455 9.57 PPARG FOXO1
28 positive regulation of superoxide dismutase activity GO:1901671 9.54 SIRT3 RGN
29 protein deacetylation GO:0006476 9.5 SIRT6 SIRT3 SIRT1
30 histone H3-K9 deacetylation GO:1990619 9.48 SIRT6 SIRT1
31 histone H3-K9 modification GO:0061647 9.46 SIRT6 SIRT1
32 protein ADP-ribosylation GO:0006471 9.26 SIRT6 SIRT3 SIRT1 PARP1
33 aging GO:0007568 9.17 WRN TP63 SOD2 SIRT3 RGN PDGFRB

Molecular functions related to Aging according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.15 WRN TP63 SOD2 REST PPARG PARP1
2 identical protein binding GO:0042802 10.08 TP63 SOD2 SIRT1 PPARG PARP1 NAMPT
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 10.05 TP63 SIRT1 REST PPARG HIF1A FOXO3
4 chromatin binding GO:0003682 9.93 WRN TP63 REST PPARG FOXO1
5 DNA-binding transcription factor activity GO:0003700 9.93 TP63 REST PPARG HIF1A FOXO3 FOXO1
6 sequence-specific DNA binding GO:0043565 9.87 TP63 SIRT3 REST PPARG HIF1A FOXO3
7 transcription regulatory region sequence-specific DNA binding GO:0000976 9.85 TP63 REST PPARG FOXO3
8 transcription factor binding GO:0008134 9.83 SIRT1 REST PPARG PARP1 HIF1A
9 p53 binding GO:0002039 9.7 TP63 SIRT1 HIF1A
10 enzyme binding GO:0019899 9.7 SOD2 SIRT3 SIRT1 PPARG PDGFRB PARP1
11 deacetylase activity GO:0019213 9.57 SIRT6 SIRT1
12 protein deacetylase activity GO:0033558 9.56 SIRT6 SIRT1
13 NAD+ binding GO:0070403 9.54 SIRT6 SIRT3 SIRT1
14 NAD-dependent protein deacetylase activity GO:0034979 9.43 SIRT6 SIRT3 SIRT1
15 NAD-dependent histone deacetylase activity (H3-K9 specific) GO:0046969 9.4 SIRT6 SIRT1
16 NAD+ ADP-ribosyltransferase activity GO:0003950 9.26 SIRT6 SIRT3 SIRT1 PARP1
17 NAD-dependent histone deacetylase activity GO:0017136 8.8 SIRT6 SIRT3 SIRT1

Sources for Aging

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....